## Sandra Garcet

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4533601/publications.pdf

Version: 2024-02-01

45 papers 1,934 citations

304602 22 h-index 42 g-index

48 all docs 48 docs citations

48 times ranked 2086 citing authors

#	Article	lF	CITATIONS
1	Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial. Journal of the American Academy of Dermatology, 2018, 78, 872-881.e6.	0.6	265
2	Efficacy and safety of ustekinumab treatment in adults with moderateâ€toâ€severe atopic dermatitis. Experimental Dermatology, 2017, 26, 28-35.	1.4	182
3	An Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease. Journal of Investigative Dermatology, 2017, 137, 603-613.	0.3	156
4	Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab. Journal of Allergy and Clinical Immunology, 2019, 143, 142-154.	1.5	135
5	Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis. Journal of Allergy and Clinical Immunology, 2019, 144, 144-156.	1.5	99
6	Autoantigens <scp>ADAMTSL</scp> 5 and <scp>LL</scp> 37 are significantly upregulated in active Psoriasis and localized with keratinocytes, dendritic cells and other leukocytes. Experimental Dermatology, 2017, 26, 1075-1082.	1.4	89
7	The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study. Journal of the American Academy of Dermatology, 2020, 83, 1341-1348.	0.6	<b>7</b> 2
8	A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitis. Journal of Allergy and Clinical Immunology, 2016, 138, 169-178.	1.5	62
9	Nonlesional atopic dermatitis skin shares similar Tâ€cell clones with lesional tissues. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 2017-2025.	2.7	62
10	Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa. Journal of Allergy and Clinical Immunology, 2021, 147, 2213-2224.	1.5	59
11	Phase 2a randomized clinical trial of dupilumab (antiâ€ILâ€4Rα) for alopecia areata patients. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 897-906.	2.7	51
12	Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab. Journal of Allergy and Clinical Immunology, 2019, 143, 2158-2169.	1.5	47
13	Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment. Journal of Investigative Dermatology, 2018, 138, 273-281.	0.3	40
14	Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis. Journal of Allergy and Clinical Immunology, 2020, 145, 922-932.	1.5	40
15	Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis. Journal of Investigative Dermatology, 2020, 140, 1546-1555.e4.	0.3	40
16	Cutaneous p38 mitogen-activated protein kinase activation triggers psoriatic dermatitis. Journal of Allergy and Clinical Immunology, 2019, 144, 1036-1049.	1.5	37
17	Aberrant connective tissue differentiation towards cartilage and bone underlies human keloids in African Americans. Experimental Dermatology, 2017, 26, 721-727.	1.4	35
18	Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis. Journal of Allergy and Clinical Immunology, 2022, 149, 1402-1412.	1.5	35

#	Article	IF	CITATIONS
19	Modulation of inflammatory gene transcripts in psoriasis vulgaris: Differences between ustekinumab and etanercept. Journal of Allergy and Clinical Immunology, 2019, 143, 1965-1969.	1.5	34
20	In-Depth Analysis of the Hidradenitis Suppurativa Serum Proteome Identifies Distinct Inflammatory Subtypes. Journal of Investigative Dermatology, 2021, 141, 2197-2207.	0.3	34
21	Weekly administration of brodalumab in hidradenitis suppurativa: an openâ€label cohort study. British Journal of Dermatology, 2021, 184, 350-352.	1.4	28
22	Synergistic cytokine effects as apremilast response predictors in patients with psoriasis. Journal of Allergy and Clinical Immunology, 2018, 142, 1010-1013.e6.	1.5	27
23	<scp>Interleukinâ€₹7RA</scp> blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum. British Journal of Dermatology, 2022, 187, 223-233.	1.4	27
24	Signalling of multiple interleukin (IL)â€17 family cytokines via ILâ€17 receptor A drives psoriasisâ€related inflammatory pathways. British Journal of Dermatology, 2021, 185, 585-594.	1.4	26
25	Dust mite induces multiple polar T cell axes in human skin. Clinical and Experimental Allergy, 2017, 47, 1648-1660.	1.4	22
26	Proportion of CD4+CD49b+LAG-3+ Type 1 Regulatory T Cells in the Blood of Psoriasis PatientsÂlnversely Correlates with Psoriasis Area and Severity Index. Journal of Investigative Dermatology, 2018, 138, 2669-2672.	0.3	21
27	The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris. Journal of the American Academy of Dermatology, 2022, 86, 322-330.	0.6	20
28	Secukinumab lowers expression of ACE2 in affected skin of patients with psoriasis. Journal of Allergy and Clinical Immunology, 2021, 147, 1107-1109.e2.	1.5	18
29	Largeâ€scale serum analysis identifies unique systemic biomarkers in psoriasis and hidradenitis suppurativa*. British Journal of Dermatology, 2022, 186, 684-693.	1.4	16
30	Novel immune signatures associated with dysplastic naevi and primary cutaneous melanoma in human skin. Experimental Dermatology, 2019, 28, 35-44.	1.4	15
31	Improving evaluation of drugs in atopic dermatitis by combining clinical and molecular measures. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3622-3625.e19.	2.0	15
32	Comparing cutaneous molecular improvement with different treatments in atopic dermatitis patients. Journal of Allergy and Clinical Immunology, 2020, 145, 1285-1288.	1.5	15
33	Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study. Lancet Rheumatology, The, 2021, 3, e204-e213.	2.2	15
34	High inflammation in hidradenitis suppurativa extends to perilesional skin and can be subdivided by lipocalin-2 expression. Journal of Allergy and Clinical Immunology, 2022, 149, 135-144.e12.	1.5	14
35	IL-36 and IL-17A Cooperatively Induce a Psoriasis-Like Gene Expression Response inÂHumanÂKeratinocytes. Journal of Investigative Dermatology, 2021, 141, 2086-2090.	0.3	13
36	Persistence of Inflammatory Phenotype in Residual Psoriatic Plaques in Patients on Effective Biologic Therapy. Journal of Investigative Dermatology, 2020, 140, 1015-1025.e4.	0.3	12

#	Article	IF	CITATIONS
37	A phase I, randomized, doubleâ€blind study to assess the safety, tolerability and efficacy of the topical RORC2 inverse agonist PFâ€06763809 in participants with mildâ€toâ€moderate plaque psoriasis. Clinical and Experimental Dermatology, 2021, 46, 122-129.	0.6	9
38	Molecular Profiling of Immune Activation Associated with Regression of Melanoma Metastases Induced by Diphencyprone. Journal of Investigative Dermatology, 2016, 136, 2101-2103.	0.3	8
39	Canal shaping with a reciprocating system is easy to learn. International Endodontic Journal, 2019, 52, 1244-1249.	2.3	8
40	Obesity and ethnicityÂalter gene expression in skin. Scientific Reports, 2020, 10, 14079.	1.6	8
41	The erythema Qâ€score, an imaging biomarker for redness in skin inflammation. Experimental Dermatology, 2021, 30, 377-383.	1.4	8
42	T <sub>H</sub> 2 cytokines and <i>Staphylococcus aureus</i> cooperatively induce atopic dermatitisâ€like transcriptomes. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3534-3537.	2.7	7
43	Ustekinumab reduces serum protein levels associated with cardiovascular risk in psoriasis vulgaris. Experimental Dermatology, 2022, 31, 1341-1351.	1.4	6
44	Assessing the responsiveness of sonographic biomarkers to Brodalumab therapy in Hidradenitis Suppurativa. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e884-e887.	1.3	1
45	OP0166â€Comparative evaluation of cellular and molecular changes associated with response to selective il-23 blockade vs dual il-12/23 blockade in psoriasis skin. , 2018, , .		1